Compare MPLX LP (MPLX) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs 10X Genomics Inc — how do they compare? MPLX LP trades at $60.05 (market cap $60.66B), while 10X Genomics Inc trades at $67.62 (market cap $8.55B). The key difference: MPLX LP is far larger — about 7.1× 10X Genomics Inc's market cap, and MPLX LP pays a 7.2% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| MPLX | TXG | |
|---|---|---|
Market Cap | $60.66B | $8.55B |
Sector | Technology | Health |
52-Week High | $60.51 | $67.29 |
52-Week Low | $47.80 | $11.34 |
Enterprise Value | $85.76B | $8.08B |
Dividend Yield | 7.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $59.83, up 0.27% with strong technical momentum as moving averages signal bullish conditions. The company demonstrates robust profitability with 40.45% net income margin and 33.95% ROE, though recent Q2 2026 earnings matched expectations without beating. Analyst consensus remains strongly bullish with 19 buy ratings and a $64.00 price target, representing 7% upside potential. Recent news highlights management's commitment to 12.5% annual distribution growth through 2027.
MPLX offers attractive income with 7%+ yield and distribution growth potential, supported by fee-based midstream operations. Key risks include rising leverage approaching 4x and exposure to energy market volatility. The stock presents a compelling value proposition for income-focused investors seeking energy infrastructure exposure with growth catalysts from ongoing capacity expansions.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
